{"id":69850,"date":"2022-10-25T13:37:00","date_gmt":"2022-10-25T08:07:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=69850"},"modified":"2022-10-25T14:50:15","modified_gmt":"2022-10-25T09:20:15","slug":"pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/","title":{"rendered":"Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39%"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1363069559\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>Laurus Labs, a pharmaceutical company has been on the losing run for three sessions in a row. Its shares fell by 5.56% on Tuesday\u2019s early trades and were quoting at \u20b9 453 levels. Its shares were at \u20b9 525 levels on October 21, 2022, and the current share price indicates a fall of 13.71% in the past three sessions.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3194164948\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>The company\u2019s share price took a downturn after it missed the expected September quarter (Q2FY23) earnings led by high industry-wide channel inventory, slower demand and pricing pressure in antiretroviral (ARV) formulations and active pharmaceutical ingredients (APIs), according to analysts.&nbsp;<\/p><p>Motilal Oswal has cut its EPS estimates by 8 per cent for FY23 and 9 per cent for FY24 to factor in a steep price erosion in ARV products, lesser tender wins in ARV formulation and increased overall operational cost. The brokerage values the stock at 23 times 12-month forward earnings and has maintained a buy rating with a target price of \u20b9 610. This translates to an upside of 34.65% as compared to its current share price.&nbsp;<\/p><p>ICICI Direct has a \u2018Buy\u2019 call on the shares with a target price of \u20b9 630. This translates to an upside of 39.07% as compared to the current share price. The brokerage continues to remain positive on the stock amid growing demand for NCE drug substances and products with ongoing supplies for seven commercial products and a visible order book.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-16359055\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>In the latest quarter, Laurus Labs\u2019 consolidated net profit increased by \u20b9 14% to \u20b9 233 crores as compared to \u20b9 204 crores in September 2021. Its revenue from operations increased to \u20b9 1576 crores from \u20b9 1203 crores in September 2021.&nbsp;<\/p><p><strong>Written by Simran Bafna&nbsp;<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-1822259184\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Laurus Labs, a pharmaceutical company has been on the losing run for three sessions in a row. Its shares fell by 5.56% on Tuesday\u2019s early trades and were quoting at \u20b9 453 levels. Its shares were at \u20b9 525 levels on October 21, 2022, and the current share price indicates a fall of 13.71% in [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":25861,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[4865,31],"tags":[],"class_list":["post-69850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39% - Trade Brains Features<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39%\" \/>\n<meta property=\"og:description\" content=\"Laurus Labs, a pharmaceutical company has been on the losing run for three sessions in a row. Its shares fell by 5.56% on Tuesday\u2019s early trades and were quoting at \u20b9 453 levels. Its shares were at \u20b9 525 levels on October 21, 2022, and the current share price indicates a fall of 13.71% in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-25T08:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-25T09:20:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/\",\"name\":\"Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39% - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\",\"datePublished\":\"2022-10-25T08:07:00+00:00\",\"dateModified\":\"2022-10-25T09:20:15+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39% - Trade Brains Features","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/","og_locale":"en_US","og_type":"article","og_title":"Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39%","og_description":"Laurus Labs, a pharmaceutical company has been on the losing run for three sessions in a row. Its shares fell by 5.56% on Tuesday\u2019s early trades and were quoting at \u20b9 453 levels. Its shares were at \u20b9 525 levels on October 21, 2022, and the current share price indicates a fall of 13.71% in [&hellip;]","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2022-10-25T08:07:00+00:00","article_modified_time":"2022-10-25T09:20:15+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_image":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/","name":"Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39% - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","datePublished":"2022-10-25T08:07:00+00:00","dateModified":"2022-10-25T09:20:15+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-tanks-14-in-3-days-analysts-see-an-upside-of-up-to-39\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma Stock tanks 14% in 3 days; Analysts see an upside of up to 39%"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/69850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=69850"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/69850\/revisions"}],"predecessor-version":[{"id":69870,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/69850\/revisions\/69870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/25861"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=69850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=69850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=69850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}